Aspeya Denmark A/S: Financial statements 2025
CVR: 44838206
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Aspeya Denmark A/S (CVR 44838206) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -5,816,709 and a net result of DKK -14,892,772. Equity in the 2025 report amounted to DKK 2,194,236. The solvency ratio was 31.3%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -5,816,709
- Profit/Loss
- DKK -14,892,772
- Equity
- DKK 2,194,236
- Total Assets
- DKK 7,011,265
- Employees
- 2
Official annual report
How creditworthy is Aspeya Denmark A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Aspeya Denmark A/S has published its interim report for the period May 16, 2024 to December 31, 2024.
As of June 1, 2025, Christopher Beck Lambert is registered as director of Aspeya Denmark A/S.
As of June 1, 2025, Joel Benjamin Rubenstein has stepped down as director of Aspeya Denmark A/S.
On January 1, 2025, the company changed its name from Vectura Fertin Pharma Denmark A/S to Aspeya Denmark A/S.
About Aspeya Denmark A/S
Aspeya Denmark A/S is a Danish company of the type Aktieselskab based in Vejle, founded in 2024. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Vectura Fertin Pharma Denmark A/S. The management consists of Christopher Beck Lambert. The board consists of Helle Egdal Nielsen (chair), Christopher Beck Lambert and Michael Henrik Thomsen. The company is owned by Aspeya Inc.. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -5,816,709 and a net result of DKK -14,892,772. Equity in the 2025 report amounted to DKK 2,194,236.